BackgroundCirculating tumour DNA (ctDNA) liquid biopsy is now established across oncology for early cancer detection, minimal residual disease surveillance, and treatment monitoring. Detection thresholds for all current ctDNA assays are derived empirically through receiver operating characteristic analysis on training cohorts--a statistically valid but theoretically uninformed approach that does not specify the minimum detectable tumour fraction given assay technical characteristics, nor identify when increasing sequencing depth ceases to provide additional clinical information [Cabello-Aguilar et al., 2025, Pantel and Alix-Panabieres, 2024].
MethodsWe model ctDNA detection as a binary hypothesis testing problem with Binomial-distributed mutant allele counts against a sequencing error noise floor. The Neyman-Pearson lemma [Kay, 1998] is applied to derive the uniformly most powerful detector and the minimum detectable tumour fraction in closed form. The sequencing assay is modelled as a binary symmetric channel and Shannon channel capacity [Shannon, 1948] is calculated. Empirical validation uses n = 61 data points extracted from five published peer-reviewed analytical validation studies across five independent institutions in the US and EU (2018-2025): Yu et al. [2022], Stetson et al. [2018], Frydendahl et al. [2023], Northcott et al. [2024], and Cheng et al. [2025].
Walinjkar, A. et al. · CC-BY 4.0